

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056470	A2	20070518	WO 2006-US43516	20061108
WO 2007056470	A3	20070809		
AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MN, MZ, NA, NC, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SB, SE, CG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TF, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ME, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MU, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2005-734798P P 20051108
US 2006-820561P P 20060727

IT 111358-88-4, CEP-701 120685-11-2, PKC-412 139987-54-5, OSI-7904
152459-95-5, Imatinib 179324-69-7, VELCADE 183321-74-6, Erlotinib
184475-35-2, ZD1839 194413-58-6, Semaxanib 212141-54-3, Vatalanib
216974-75-3, Bevacizumab 219923-05-4, ZD6126 231277-92-2,
Lapatinib 284461-73-0, Sorafenib 288383-20-0, AZD2171
347396-82-1, Ranibizumab 387867-13-2, MLN-518 443913-73-3, ZD6474
453562-69-1, AMG706 557795-19-4, Sunitinib 777080-36-1, AG 13736
937176-80-2, EXEL 2880 937178-31-9, CHIR 265

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(anti-neuropilin 1 antagonistic antibodies for research, diagnosis and
therapy of cancer and angiogenesis-associated disease)

L26 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:332801 CAPLUS

DOCUMENT NUMBER: 146:309324

TITLE: Method of treating cancer, especially soft tissue
sarcoma utilizing gemcitabine in combination with
docetaxel and anti-VEGF therapy (bevacizumab)

INVENTOR(S): Verschraegen, Claire

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 16pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007065449	A1	20070322	US 2006-522687	20060915
PRIORITY APPLN. INFO.			US 2005-717652P	P 20050916
IT 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 204005-46-9, SU5416 212142-18-2, RPTK787 216974-75-3, Bevacizumab 219923-05-4, ZD6126 252916-29-3, SU6668 257938-36-6, ZD4190 288383-20-0, AZD2171 341033-54-7, SU11248 402857-58-3, CEP-7055 443913-73-3, ZD6474				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(treating soft tissue sarcoma utilizing gemcitabine in combination with
docetaxel and anti-VEGF therapy (bevacizumab))

L26 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:55068 CAPLUS
 DOCUMENT NUMBER: 142:127565
 TITLE: AZD2171-ZD6126 combination with optional ionizing radiation for the production of an antiangiogenic and/or vascular permeability-reducing effect and the treatment of cancer
 INVENTOR(S): Wedge, Stephen Robert
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed., Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004871	A1	20050120	WO 2004-GB2937	20040707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004255023	A1	20050120	AU 2004-255023	20040707
CA 2531643	A1	20050120	CA 2004-2531643	20040707
EP 1651227	A1	20060503	EP 2004-743280	20040707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1819830	A	20060816	CN 2004-80019488	20040707
BR 2004012450	A	20060919	BR 2004-12450	20040707
JP 2007526887	T	20070920	JP 2006-518354	20040707
NO 2005006171	A	20060207	NO 2005-6171	20051223
US 2006160775	A1	20060720	US 2006-563440	20060105
MX 2006PA00413	A	20060317	MX 2006-PA413	20060110
PRIORITY APPLN. INFO.:			GB 2003-16123	A 20030710
			WO 2004-GB2937	W 20040707

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 219923-05-4, ZD6126 288383-20-0, AZD 2171 824933-09-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(AZD2171-ZD6126 combination with optional ionizing radiation for production of antiangiogenic and/or vascular permeability-reducing effect and treatment of cancer)

L26 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2007:75099 USPATFULL
 TITLE: Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
 INVENTOR(S): Verschraegen, Claire, Albuquerque, NM, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2007065449 A1 20070322
APPLICATION INFO.: US 2006-522687 A1 20060915 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-717652P	20050916 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	COLEMAN SUDOL SAPONE, P.C., 711 COLORADO AVENUE, BRIDGEPORT, CT, 06605-1601, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1545	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT	95058-81-4, Gemcitabine 114977-28-5, Docetaxel 204005-46-9, SU5416 212142-18-2, PTK787 216974-75-3, Bevacizumab 219923-05-4 , ZD6126 252916-29-3, SU6668 257938-36-6, ZD4190 288383-20-0 , AZD2171 341031-54-7, SU11248 402857-58-3, CEP-7055 443913-73-3, ZD6474 (treating soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab))	

L26 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2006:189335 USPATFULL
TITLE: Combination therapy
INVENTOR(S): Wedge, Stephen Robert, Cheshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006160775	A1	20060720
APPLICATION INFO.:	US 2004-563440	A1	20040707 (10)
	WO 2004-GB2937		20040707
			20060105 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16123	20030710
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	817	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **219923-05-4**, ZD6126 **288383-20-0**, AZD 2171 824933-09-7 (AZD2171-ZD6126 combination with optional ionizing radiation for production of antiangiogenic and/or vascular permeability-reducing effect and treatment of cancer)

=>
=> d his

(FILE 'HOME' ENTERED AT 14:19:21 ON 25 SEP 2007)

FILE 'REGISTRY' ENTERED AT 14:19:33 ON 25 SEP 2007
E AZD2171

E AZD2171/CN
E AZD 2171/CN
L1 1 S E3
E ZD 6126/CN
L2 1 S E3

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL, USPATOLD, USPAT2'
ENTERED AT 14:28:21 ON 25 SEP 2007

SET MSTEP ON

L3 0 FILE MEDLINE
L4 0 FILE BIOSIS
L5 0 FILE EMBASE
L6 40 FILE CAPLUS
L7 13 FILE USPATFULL
L8 0 FILE USPATOLD
L9 0 FILE USPAT2

TOTAL FOR ALL FILES

L10 53 S L1
L11 0 FILE MEDLINE
L12 73 FILE BIOSIS
L13 173 FILE EMBASE
L14 73 FILE CAPLUS
L15 12 FILE USPATFULL
L16 0 FILE USPATOLD
L17 1 FILE USPAT2

TOTAL FOR ALL FILES

L18 332 S L2
L19 0 FILE MEDLINE
L20 0 FILE BIOSIS
L21 0 FILE EMBASE
L22 3 FILE CAPLUS
L23 2 FILE USPATFULL
L24 0 FILE USPATOLD
L25 0 FILE USPAT2

TOTAL FOR ALL FILES

L26 5 S L18 AND L10

=> fil stnguide

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
49.77	85.38

FILE 'STNGUIDE' ENTERED AT 15:40:34 ON 25 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.


LAST RELOADED: Sep 24, 2007 (20070924/UP)

=> d 11;d 12

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 288383-20-0. REGISTRY
ED Entered STN: 08 Sep 2000
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy] - (CA INDEX NAME)
OTHER NAMES:

CN 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
CN AZD 2171
CN Cediranib
DR 790713-41-6
MF C25 H27 F N4 O3
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSDRUGNEWS, IMSPATENTS,
IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

39 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
40 REFERENCES IN FILE CAPLUS (1907 TO DATE)

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 219923-05-4 REGISTRY
ED Entered STN: 23 Feb 1999
CN Acetamide, N-[(5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo[a,c]cyclohepten-5-yl]-(CA INDEX NAME)
OTHER NAMES:
CN ANG 453
CN AZD 6126
CN N-Acetylcolchinol dihydrogenphosphate
CN ZD 6126
CN ZM 445526
FS STEREOSEARCH
MF C20 H24 N O8 P
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, IPA,
PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry...

OPO₃H₂

OMe

MeO

S NHAC

MeO

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

73 REFERENCES IN FILE CA (1907 TO DATE)
73 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.66	92.16

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 16:00:36 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 24, 2007 (20070924/UP).

=>

=>

=>

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
5.28	97.44

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 16:53:13 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 24, 2007 (20070924/UP).

=> d his

(FILE 'HOME' ENTERED AT 14:19:21 ON 25 SEP 2007)

FILE 'REGISTRY' ENTERED AT 14:19:33 ON 25 SEP 2007

E AZD2171

E AZD2171/CN

E AZD 2171/CN

L1 1 S E3

E ZD 6126/CN

L2 1 S E3

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL, USPATOLD, USPAT2'
ENTERED AT 14:28:21 ON 25 SEP 2007

SET MSTEP ON

L3 0 FILE MEDLINE

L4 0 FILE BIOSIS
L5 0 FILE EMBASE
L6 40 FILE CAPLUS
L7 13 FILE USPATFULL
L8 0 FILE USPATOLD
L9 0 FILE USPAT2

TOTAL FOR ALL FILES

L10 53 S L1
L11 0 FILE MEDLINE
L12 73 FILE BIOSIS
L13 173 FILE EMBASE
L14 73 FILE CAPLUS
L15 12 FILE USPATFULL
L16 0 FILE USPATOLD
L17 1 FILE USPAT2

TOTAL FOR ALL FILES

L18 332 S L2
L19 0 FILE MEDLINE
L20 0 FILE BIOSIS
L21 0 FILE EMBASE
L22 3 FILE CAPLUS
L23 2 FILE USPATFULL
L24 0 FILE USPATOLD
L25 0 FILE USPAT2

TOTAL FOR ALL FILES

L26 5 S L18 AND L10

FILE 'STNGUIDE' ENTERED AT 15:40:34 ON 25 SEP 2007

FILE 'REGISTRY' ENTERED AT 15:52:14 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 15:52:15 ON 25 SEP 2007

FILE 'REGISTRY' ENTERED AT 15:53:55 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 15:53:56 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 16:00:36 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 16:53:13 ON 25 SEP 2007

=> fil MEDLINE, BIOSIS, EMBASE, CAPLUS, uspatall

COST IN U.S. DOLLARS.

SINCE FILE

TOTAL

ENTRY SESSION

FULL ESTIMATED COST

0.96

98.40

FILE 'MEDLINE' ENTERED AT 17:02:51 ON 25 SEP 2007

FILE 'BIOSIS' ENTERED AT 17:02:51 ON 25 SEP 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:02:51 ON 25 SEP 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 17:02:51 ON 25 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:02:51 ON 25 SEP 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:02:51 ON 25 SEP 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:02:51 ON 25 SEP 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l10 and py<=2003

L27 0 FILE MEDLINE

L28 0 FILE BIOSIS

L29 0 FILE EMBASE

L30 2 FILE CAPLUS

L31 2 FILE USPATFULL

L32 0 FILE USPATOLD

L33 0 FILE USPAT2

TOTAL FOR ALL FILES

L34 4 L10 AND PY<=2003

=> d 134 1-4 ibib kwic

L34 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:747609 CAPLUS

DOCUMENT NUMBER: 135:283196

TITLE: Therapeutic combinations of antihypertensive and antiangiogenic agents

INVENTOR(S): Curwen, Jon Owen; Ogilvie, Donald James

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074360	A1	20011011	WO 2001-GB1522	20010402 <-
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401854	A1	20011011	CA 2001-2401854	20010402 <-
EP 1272186	A1	20030108	EP 2001-917305	20010402 <-
EP 1272186	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009729	A	20030204	BR 2001-9729	20010402 <-
HU 200300426	A2	20030628	HU 2003-426	20010402 <-
JP 2003528917	T	20030930	JP 2001-572104	20010402 <-
EE 200200578	A	20040615	EE 2002-578	20010402
NZ 520938	A	20050826	NZ 2001-520938	20010402
AT 355065	T	20060315	AT 2001-917305	20010402
EP 1658849	A2	20060524	EP 2006-3576	20010402

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 NZ 534455 A 20070126 NZ 2001-534455 20010402
 EP 1790340 A2 20070530 EP 2007-3863 20010402
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
 IN 2002MN01149 A 20050304 IN 2002-MN1149 20020823
 ZA 2002006959 A 20031201 ZA 2002-6959 20020829 <--
 US 2003144298 A1 20030731 US 2002-240413 20021001 <--
 MX 2002PA09743 A 20030327 MX 2002-PA9743 20021003 <--
 NO 2002004814 A 20021112 NO 2002-4814 20021004 <--
 NO 323467 B1 20070521
 NO 2006002050 A 20011108 NO 2006-2050 20060508 <--
 PRIORITY APPLN. INFO.: GB 2000-8269 A 20000405
 EP 2001-917305 A3 20010402
 NZ 2001-520938 A1 20010402
 WO 2001-GB1522 W 20010402

OTHER SOURCE(S): MARPAT 135:283196
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI	WO 2001074360	A1	<u>20011011</u>	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074360	A1	20011011	WO 2001-GB1522		20010402	<--
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA	2401854	A1	20011011	CA 2001-2401854		20010402	<--
EP	1272186	A1	20030108	EP 2001-917305		20010402	<--
EP	1272186	B1	20070228				
		R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR	2001009729	A	20030204	BR 2001-9729		20010402	<--
HU	200300426	A2	20030628	HU 2003-426		20010402	<--
JP	2003528917	T	20030930	JP 2001-572104		20010402	<--
EE	200200578	A	20040615	EE 2002-578		20010402	
NZ	520938	A	20050826	NZ 2001-520938		20010402	
AT	355065	T	20060315	AT 2001-917305		20010402	
EP	1658849	A2	20060524	EP 2006-3576		20010402	
		R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ	534455	A	20070126	NZ 2001-534455		20010402	
EP	1790340	A2	20070530	EP 2007-3863		20010402	
		R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
IN	2002MN01149	A	20050304	IN 2002-MN1149		20020823	
ZA	2002006959	A	20031201	ZA 2002-6959		20020829	<--
US	2003144298	A1	20030731	US 2002-240413		20021001	<--
MX	2002PA09743	A	20030327	MX 2002-PA9743		20021003	<--
NO	2002004814	A	20021112	NO 2002-4814		20021004	<--
NO	323467	B1	20070521				
NO	2006002050	A	20011108	NO 2006-2050		20060508	<--
IT	62571-86-2, Captoril 76547-98-3, Lisinopril 288383-14-2, 288383-15-3 288383-16-4 288383-17-5 288383-18-6 288383-19-7 <u>288383-20-0</u>						

288383-21-1 288383-22-2 288383-23-3 288383-24-4 288383-25-5

288383-26-6 443913-73-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic combinations of antihypertensive and antiangiogenic agents)

L34 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:573671 CAPLUS

DOCUMENT NUMBER: 133:177183

TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.

SOURCE: PCT Int. Appl., 346 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	A1	20000817	CA 2000-2362715	20000208 <--
EP 1154774	A1	20011121	EP 2000-902730	20000208 <--
EP 1154774	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102314	T2	20020121	TR 2001-2314	20000208 <--
BR 2000008128	A	20020213	BR 2000-8128	20000208 <--
HU 200104964	A2	20020429	HU 2001-4964	20000208 <--
JP 2002536414	T	20021029	JP 2000-598164	20000208 <--
JP 3893026	B2	20070314		
EE 200100409	A	20021216	EE 2001-409	20000208 <--
AU 763618	B2	20030731	AU 2000-24475	20000208 <--
NZ 513204	A	20040430	NZ 2000-513204	20000208
CN 1597667	A	20050323	CN 2004-10058982	20000208
TR 200500745	T2	20050523	TR 2005-745	20000208
NZ 530832	A	20050527	NZ 2000-530832	20000208
EP 1553097	A1	20050713	EP 2005-4285	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 298237	T	20050715	AT 2000-902730	20000208
RU 2262935	C2	20051027	RU 2001-124816	20000208
PT 1154774	T	20051031	PT 2000-902730	20000208
ES 2242596	T3	20051116	ES 2000-902730	20000208
IN 2000DE00115	A	20050311	IN 2000-DE115	20000211
IN 2001MN00893	A	20070525	IN 2001-MN893	20010726
ZA 2001006340	A	20021101	ZA 2001-6340	20010801 <--

NO 2001003882	A	20011009	NO 2001-3882	20010809 <--
NO 321604	B1	20060612		
MX 2001PA08182	A	20030820	MX 2001-PA8182	20010810 <--
HK 1041212	A1	20051202	HK 2002-102781	20020412
US 7074800	B1	20060711	US 2002-913020	20020506
NO 2005002773	A	20011009	NO 2005-2773	20050608 <--
US 2006004017	A1	20060105	US 2005-169122	20050629
JP 2006273860	A	20061012	JP 2006-129249	20060508
PRIORITY APPLN. INFO.:			EP 1999-400305	A 19990210
			EP 2000-902730	A3 20000208
			JP 2000-598164	A3 20000208
			WO 2000-GB373	W 20000208
			US 2002-913020	A3 20020506

OTHER SOURCE(S): MARPAT 133:177183
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI	WO 2000047212 A1	<u>20000817</u>	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--	
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
CA	2362715	A1	20000817	CA 2000-2362715	20000208 <--	
EP	1154774	A1	20011121	EP 2000-902730	20000208 <--	
EP	1154774	B1	20050622			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR	200102314	T2	20020121	TR 2001-2314	20000208 <--	
BR	2000008128	A	20020213	BR 2000-8128	20000208 <--	
HU	200104964	A2	20020429	HU 2001-4964	20000208 <--	
JP	2002536414	T	20021029	JP 2000-598164	20000208 <--	
JP	3893026	B2	20070314			
EE	200100409	A	20021216	EE 2001-409	20000208 <--	
AU	763618	B2	20030731	AU 2000-24475	20000208 <--	
NZ	513204	A	20040430	NZ 2000-513204	20000208	
CN	1597667	A	20050323	CN 2004-10058982	20000208	
TR	200500745	T2	20050523	TR 2005-745	20000208	
NZ	530832	A	20050527	NZ 2000-530832	20000208	
EP	1553097	A1	20050713	EP 2005-4285	20000208	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
AT	298237	T	20050715	AT 2000-902730	20000208	
RU	2262935	C2	20051027	RU 2001-124816	20000208	
PT	1154774	T	20051031	PT 2000-902730	20000208	
ES	2242596	T3	20051116	ES 2000-902730	20000208	
IN	2000DE00115	A	20050311	IN 2000-DE115	20000211	
IN	2001MN00893	A	20070525	IN 2001-MN893	20010726	
ZA	2001006340	A	20021101	ZA 2001-6340	20010801 <--	
NO	2001003882	A	20011009	NO 2001-3882	20010809 <--	
NO	321604	B1	20060612			
MX	2001PA08182	A	20030820	MX 2001-PA8182	20010810 <--	
HK	1041212	A1	20051202	HK 2002-102781	20020412	
US	7074800	B1	20060711	US 2002-913020	20020506	
NO	2005002773	A	20011009	NO 2005-2773	20050608 <--	

	US 2006004017	A1	20060105	US 2005-169122	20050629
	JP 2006273860	A	20061012	JP 2006-129249	20060508
IT	170147-76-9P, 5-Hydroxy-1-(tert-butoxycarbonyl)-2,3-dihydroindole 172078-33-0P, 5-Hydroxy-2,3-dihydro-1H-indole 288382-01-4P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2-naphthylloxy)quinazoline 288382-02-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288382-04-7P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288382-06-9P, 6-Methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-(quinolin-7-yloxy)quinazoline 288382-10-5P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-12-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288382-14-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288382-16-1P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(quinolin-7-yloxy)quinazoline 288382-18-3P, 6-Methoxy-7-[(1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288382-20-7P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288382-22-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-24-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-26-3P, 6-Methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-28-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-30-9P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288382-32-1P, 7-(3-(N,N-Dimethylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-34-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288382-36-5P, 7-[2-(N,N-Diethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-37-6P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-38-7P, 4-(2-Methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-39-8P, 4-(2-Methylindol-5-yloxy)-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-40-1P, 4-(2-Methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-41-2P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline 288382-42-3P, 7-[3-(Methylsulfonyl)propoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-43-4P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288382-44-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)quinazoline 288382-45-6P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-46-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288382-47-8P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-48-9P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-49-0P, 7-[3-(Ethylsulfonyl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-50-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-51-4P, 7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-52-5P, 7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-53-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methylamino)ethoxy]quinazoline 288382-54-7P, 7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-55-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-56-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-57-0P, 4-(Indol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288382-58-1P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-59-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-				

methylsulfonylpropoxy)quinazoline 288382-60-5P, 7-[(1-Cyanomethyl)piperidin-4-yl)methoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-61-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinooethoxy)quinazoline 288382-62-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline 288382-63-8P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-methylpiperidin-3-yl)methoxy)quinazoline 288382-64-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288382-65-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288382-66-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-67-2P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-68-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-69-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy]quinazoline 288382-70-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-71-8P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-72-9P 288382-73-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288382-74-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-75-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yloxy)ethoxy]quinazoline 288382-76-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methyl-N-methylsulfonylamino)ethoxy]quinazoline 288382-77-4P, 7-[2-[(1-(2-Cyanoethyl)piperidin-4-yl)oxy]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-78-5P, 4-(2-Methylindol-5-yloxy)-7-[3-(pyrrolidinyl)propoxy]quinazoline 288382-79-6P, 4-(2-Methylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288382-80-9P, 4-(2-Methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-81-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288382-82-1P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-83-2P, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-84-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-85-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-86-5P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-87-6P, 7-[[1-(2-Methoxyethyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-88-7P, 7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-89-8P, 7-[2-[1-(2-Methoxyethyl)piperidin-4-yl]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-90-1P, 7-(2-Hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-91-2P, 7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-92-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-93-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-94-5P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-95-6P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288382-96-7P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288382-97-8P, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-98-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-[2-(pyrrolidin-1-yl)ethyl)piperidin-4-yl)methoxy]quinazoline 288382-99-0P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-

methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-06-2P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-07-3P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-08-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-(2-morpholinoethyl)piperidin-4-yl)methoxy]quinazoline 288383-09-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-10-8P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-11-9P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)quinazoline 288383-12-0P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288383-13-1P, 4-(6-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-14-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-22-2P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288383-26-6P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-27-7P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-6-yloxy)quinazoline 288383-28-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1-naphthyl)quinazoline 288383-29-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-morpholinopropoxy)quinazoline 288383-33-5P, 6,7-Dimethoxy-4-(quinolin-7-yloxy)quinazoline 288383-34-6P, (S)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-35-7P, (R)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-37-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-(2-methylsulfonylethyl)piperidin-4-yl)methoxy]quinazoline 288383-38-0P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-39-1P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-40-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-41-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)quinazoline 288383-42-6P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)quinazoline 288383-43-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-6-yloxy)quinazoline 288383-44-8P, 4-((1,3-Benzodioxol-5-yl)amino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-45-9P, 4-(1H-Indazol-6-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-46-0P, 4-(1H-Indazol-5-ylamino)-6-methoxy-7-(3-

morpholinopropoxy)quinazoline 288383-47-1P, 4-((1,3-Benzothiazol-6-yl)amino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-48-2P, 6-Methoxy-4-((2-methyl-1,3-benzothiazol-5-yl)amino)-7-(3-morpholinopropoxy)quinazoline 288383-49-3P, 4-(2,3-Dihydro-1H-inden-5-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-50-6P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-52-8P, 6-Methoxy-4-((4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-53-9P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-54-0P, 6-Methoxy-4-((4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-55-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-56-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-57-3P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-58-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-59-5P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-60-8P, 6-Methoxy-4-(2-methylquinolin-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-61-9P, 6-Methoxy-7-[(1-(2-methylsulfonylethyl)piperidin-4-yl)methoxy]-4-(2-methylquinolin-7-yloxy)quinazoline 288383-63-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-66-4P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288383-67-5P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-68-6P, 7-[2-(N,N-Dimethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-70-0P, 6-Methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-75-5P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline 288383-76-6P, 6-Methoxy-7-[(1-(2-methoxyethyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-81-3P, 7-(3-Chloropropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-82-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[(1-(tert-butoxycarbonyl)piperidin-4-yl)oxylethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-88-0P, 4-(2-Methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288383-89-1P, 4-(2-Methylindol-5-yloxy)-7-[3-(piperidin-1-yl)propoxy]quinazoline 288383-90-4P, 7-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)-4-(2-methylindol-5-yloxy)quinazoline 288383-92-6P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288383-94-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288383-95-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288383-96-0P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-97-1P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-98-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline 288383-99-3P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-oxopyrrolidin-1-yl)ethoxy]quinazoline 288384-00-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288384-01-0P, 4-(2,3-Dimethylindol-5-yloxy)-7-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-6-methoxyquinazoline 288384-02-1P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-03-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-04-3P, 4-(2,3-Dimethylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]-6-methoxyquinazoline 288384-05-4P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(4-

pyridyloxy)ethoxy]quinazoline 288384-06-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-08-7P, 7-Benzyl oxy-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-09-8P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-10-1P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline 288384-11-2P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-12-3P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-14-5P, 4-(2,3-Dimethylindol-5-yloxy)-7-(3-ethylsulfonylpropoxy)-6-methoxyquinazoline 288384-16-7P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-(3-morpholinopropoxy)quinazoline 288384-19-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[(E)-4-(pyrrolidin-1-yl)but-2-en-1-yloxy]quinazoline 288384-21-4P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(5-methyl-1H-[1,2,4]triazol-1-yl)propoxy]quinazoline 288384-24-7P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-25-8P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(1-methylimidazol-2-yl)ethoxy]quinazoline 288384-26-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288384-27-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288384-28-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288384-29-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-furylmethoxy)quinazoline 288384-30-5P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(N,N-dimethylamino)ethoxy]quinazoline 288384-31-6P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288384-32-7P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]quinazoline 288384-33-8P, 7-[2-(5,5-Dimethyl-1,3-dioxan-2-yl)ethoxy]-4-(2,3-dimethylindol-5-ylamino)-6-methoxyquinazoline 288384-34-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288384-35-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(pyridazin-4-yl)amino]ethoxy]quinazoline 288384-36-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288384-37-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(3-pyridyl)ethoxy]quinazoline 288384-38-3P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(2-oxopyrrolidin-1-yl)propoxy]quinazoline 288384-39-4P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-40-7P, 4-(1,2-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-42-9P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-49-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-50-9P, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(quinolin-7-yloxy)quinazoline 288384-51-0P, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288384-52-1P, 6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(4-trifluoromethylquinolin-7-yloxy)quinazoline 288384-57-6P, 4-(3-Fluoro-2-methylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288384-59-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-63-4P, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-64-5P, 4-(Indol-4-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-65-6P, 4-(9H-Carbazol-3-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-67-8P, 4-[[7-Chloro-2-(ethoxycarbonyl)indol-5-yl]oxy]-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-69-0P, 7-Benzyl oxy-4-((1-tert-butoxycarbonyl-2,3-dimethylindol-5-yl)oxy)-6-methoxyquinazoline 288384-70-3P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-2-

yloxy)quinazoline 288384-71-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-5-yloxy)quinazoline 288384-75-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-76-9P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288384-78-1P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-82-7P, 4-(2-Carboxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-84-9P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(quinolin-7-yloxy)quinazoline 288384-85-0P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-87-2P, 6-Methoxy-4-((2-methyl-1,3-benzothiazol-5-yl)oxy)-7-(3-methylsulfonylpropoxy)quinazoline 288384-89-4P, 4-(7-Hydroxy-2-naphthyloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-93-0P, 4-(2-Chloro-1H-benzimidazol-6-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288384-95-2P, 6-Methoxy-4-(2-methyl-1H-benzimidazol-6-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-00-2P, 4-(3-Cyanoquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-10-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1,2,3,4-tetrahydroquinolin-6-yloxy)quinazoline 288385-18-2P, 4-(2,3-Dihydro-1H-indol-5-yl)oxy-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-27-3P, 6-Methoxy-7-(2-piperidinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-30-8P, 7-Benzylxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-33-1P, 7-Hydroxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-35-3P, 6-Methoxy-7-(2-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288385-38-6P, (S)-6-Methoxy-7-(5-oxopyrrolidin-2-ylmethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-39-7P, 4-(9H-Carbazol-2-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-41-1P, 7-[2-[N-(3,6-Dichloropyridazin-4-yl)-N-methylamino]ethoxy]-4-(indol-5-ylamino)-6-methoxyquinazoline 288385-43-3P, 4-(Indol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288385-44-4P, 4-(Indol-5-ylamino)-6-methoxy-7-[(3-pyridyl)methoxy]quinazoline 288385-45-5P, 4-(Indol-5-ylamino)-6-methoxy-7-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]quinazoline 288385-47-7P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-morpholinopropoxy)quinazoline 288385-49-9P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-ylamino)quinazoline 288385-50-2P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(2-piperidinoethoxy)quinazoline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization).

L34 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2006:177591 USPATFULL
 TITLE: Quinazoline derivatives as angiogenesis inhibitors
 INVENTOR(S): Stokes, Elaine S E, Macclesfield, UNITED KINGDOM
 Mckerrecher, Darren, Macclesfield, UNITED KINGDOM
 Hennequin, Laurent F A, Reims, FRANCE
 Ple, Patrick, Reims, FRANCE
 PATENT ASSIGNEE(S): AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 7074800 B1 20060711

WO 2000047212 20000817

APPLICATION INFO.: US 2000-913020 20000208 (9)

NUMBER DATE

PRIORITY INFORMATION: EP 1999-400305 19990210
 DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Raymond, Richard L.
 LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius LLP
 NUMBER OF CLAIMS: 26
 EXEMPLARY CLAIM: 1
 LINE COUNT: 12388
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI	US 7074800	B1 20060711
	WO 2000047212	20000817
IT	170147-76-9P, 5-Hydroxy-1-(tert-butoxycarbonyl)-2,3-dihydroindole 172078-33-0P, 5-Hydroxy-2,3-dihydro-1H-indole 288382-01-4P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2-naphthoxy)quinazoline 288382-02-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288382-04-7P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288382-06-9P, 6-Methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-(quinolin-7-yloxy)quinazoline 288382-10-5P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-12-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288382-14-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288382-16-1P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(quinolin-7-yloxy)quinazoline 288382-18-3P, 6-Methoxy-7-[[1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288382-20-7P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288382-22-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-24-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-26-3P, 6-Methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-28-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-30-9P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288382-32-1P, 7-(3-(N,N-Dimethylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-34-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288382-36-5P, 7-[2-(N,N-Diethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-37-6P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-38-7P, 4-(2-Methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-39-8P, 4-(2-Methylindol-5-yloxy)-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-40-1P, 4-(2-Methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-41-2P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline 288382-42-3P, 7-[3-(Methylsulfonyl)propoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-43-4P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288382-44-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)quinazoline 288382-45-6P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-46-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288382-47-8P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-48-9P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-49-0P,	

7-[3-(Ethylsulfonyl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-50-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-51-4P; 7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-52-5P; 7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-53-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methylamino)ethoxy]quinazoline 288382-54-7P; 7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-55-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-56-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-57-0P, 4-(Indol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288382-58-1P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-59-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulfonylpropoxy)quinazoline 288382-60-5P, 7-[(1-Cyanomethyl)piperidin-4-yl)methoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-61-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288382-62-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline 288382-63-8P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-methylpiperidin-3-yl)methoxy)quinazoline 288382-64-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288382-65-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288382-66-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-67-2P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-68-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-69-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy]quinazoline 288382-70-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-71-8P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-72-9P 288382-73-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288382-74-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-75-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yloxy)ethoxy]quinazoline 288382-76-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methyl-N-methylsulfonylamino)ethoxy]quinazoline 288382-77-4P, 7-[2-[(1-(2-Cyanoethyl)piperidin-4-yl)oxyl]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-78-5P, 4-(2-Methylindol-5-yloxy)-7-[3-(pyrrolidinyl)propoxy]quinazoline 288382-79-6P, 4-(2-Methylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288382-80-9P, 4-(2-Methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-81-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288382-82-1P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-83-2P, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-84-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-85-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-86-5P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-87-6P, 7-[(1-(2-Methoxyethyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-88-7P, 7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-89-8P, 7-[2-[(2-Methoxyethyl)piperidin-4-yl)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-90-1P, 7-(2-Hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-91-2P, 7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-

yloxy)quinazoline 288382-92-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-93-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-94-5P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-morpholinoproxy)quinazoline 288382-95-6P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288382-96-7P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288382-97-8P, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-98-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-[2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl]methoxy]quinazoline 288382-99-0P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-06-2P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-07-3P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-08-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-morpholinoethyl)piperidin-4-yl]methoxy]quinazoline 288383-09-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-10-8P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-11-9P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)quinazoline 288383-12-0P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288383-13-1P, 4-(6-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-14-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-22-2P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288383-26-6P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-27-7P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-6-yloxy)quinazoline 288383-28-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1-naphthyloxy)quinazoline 288383-29-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-morpholinopropoxy)quinazoline 288383-33-5P, 6,7-Dimethoxy-4-(quinolin-7-yloxy)quinazoline 288383-34-6P, (S)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-

yloxy)quinazoline 288383-35-7P, (R)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-37-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-(2-methylsulfonylethyl)piperidin-4-yl)methoxy]quinazoline 288383-38-0P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-39-1P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-40-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxylquinazoline 288383-41-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)quinazoline 288383-42-6P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)quinazoline 288383-43-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-6-yloxy)quinazoline 288383-44-8P, 4-((1,3-Benzodioxol-5-yl)amino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-45-9P, 4-(1H-Indazol-6-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-46-0P, 4-(1H-Indazol-5-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-47-1P, 4-((1,3-Benzothiazol-6-yl)amino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-48-2P, 6-Methoxy-4-((2-methyl-1,3-benzothiazol-5-yl)amino)-7-(3-morpholinopropoxy)quinazoline 288383-49-3P, 4-(2,3-Dihydro-1H-inden-5-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-50-6P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-52-8P, 6-Methoxy-4-((4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-53-9P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-54-0P, 6-Methoxy-4-((4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-55-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-56-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-57-3P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-58-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-59-5P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-60-8P, 6-Methoxy-4-(2-methylquinolin-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-61-9P, 6-Methoxy-7-[(1-(2-methylsulfonylethyl)piperidin-4-yl)methoxy]-4-(2-methylquinolin-7-yloxy)quinazoline 288383-63-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-66-4P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288383-67-5P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-68-6P, 7-[2-(N,N-Dimethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-70-0P, 6-Methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-75-5P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline 288383-76-6P, 6-Methoxy-7-[(1-(2-methoxyethyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-81-3P, 7-(3-Chloropropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-82-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[(1-(tert-butoxycarbonyl)piperidin-4-yl)oxy]ethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-88-0P, 4-(2-Methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288383-89-1P, 4-(2-Methylindol-5-yloxy)-7-[3-(piperidin-1-yl)propoxy]quinazoline 288383-90-4P, 7-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)-4-(2-methylindol-5-

yloxy)quinazoline 288383-92-6P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288383-94-8P,
4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288383-95-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288383-96-0P,
7-[2-(N,N-Diethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-97-1P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-98-2P,
4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline 288383-99-3P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-oxopyrrolidin-1-yl)ethoxy]quinazoline 288384-00-9P,
4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288384-01-0P, 4-(2,3-Dimethylindol-5-yloxy)-7-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-6-methoxyquinazoline 288384-02-1P,
4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-03-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-04-3P, 4-(2,3-Dimethylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]-6-methoxyquinazoline 288384-05-4P,
4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288384-06-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-08-7P,
7-Benzylxy-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-09-8P,
7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-10-1P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline 288384-11-2P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-12-3P,
4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-14-5P, 4-(2,3-Dimethylindol-5-yloxy)-7-(3-ethylsulfonylpropoxy)-6-methoxyquinazoline 288384-16-7P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-(3-morpholinopropoxy)quinazoline 288384-19-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[E)-4-(pyrrolidin-1-yl)but-2-en-1-yloxy]quinazoline 288384-21-4P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(5-methyl-1H-[1,2,4]triazol-1-yl)propoxy]quinazoline 288384-24-7P,
4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-25-8P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(1-methylimidazol-2-yl)ethoxy]quinazoline 288384-26-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288384-27-0P,
4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288384-28-1P,
4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288384-29-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-furylmethoxy)quinazoline 288384-30-5P,
4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(N,N-dimethylamino)ethoxy]quinazoline 288384-31-6P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288384-32-7P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]quinazoline 288384-33-8P,
7-[2-(5,5-Dimethyl-1,3-dioxan-2-yl)ethoxy]-4-(2,3-dimethylindol-5-ylamino)-6-methoxyquinazoline 288384-34-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288384-35-0P,
4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(pyridazin-4-yl)amino]ethoxy]quinazoline 288384-36-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288384-37-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(3-pyridyl)ethoxy]quinazoline 288384-38-3P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(2-oxopyrrolidin-1-yl)propoxy]quinazoline 288384-39-4P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-40-7P, 4-(1,2-Dimethylindol-5-yloxy)-6-

methoxy-7-(3-morpholinopropoxy)quinazoline 288384-42-9P,
4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-49-6P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-50-9P,
6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(quinolin-7-yloxy)quinazoline 288384-51-0P, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288384-52-1P, 6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(4-trifluoromethylquinolin-7-yloxy)quinazoline 288384-57-6P,
4-(3-Fluoro-2-methylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288384-59-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-63-4P, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-64-5P, 4-(Indol-4-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-65-6P, 4-(9H-Carbazol-3-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-67-8P,
4-[[7-Chloro-2-(ethoxycarbonyl)indol-5-yl]oxy]-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-69-0P, 7-Benzyl oxy-4-((1-tert-butoxycarbonyl-2,3-dimethylindol-5-yl)oxy)-6-methoxyquinazoline 288384-70-3P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-2-yloxy)quinazoline 288384-71-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-5-yloxy)quinazoline 288384-75-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-76-9P,
6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288384-78-1P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-82-7P,
4-(2-Carboxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-84-9P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(quinolin-7-yloxy)quinazoline 288384-85-0P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-87-2P,
6-Methoxy-4-((2-methyl-1,3-benzothiazol-5-yl)oxy)-7-(3-methylsulfonylpropoxy)quinazoline 288384-89-4P, 4-(7-Hydroxy-2-naphthyl oxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-93-0P, 4-(2-Chloro-1H-benzimidazol-6-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288384-95-2P,
6-Methoxy-4-(2-methyl-1H-benzimidazol-6-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-00-2P, 4-(3-Cyanoquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-10-4P,
6-Methoxy-7-(3-morpholinopropoxy)-4-(1,2,3,4-tetrahydroquinolin-6-yloxy)quinazoline 288385-18-2P, 4-(2,3-Dihydro-1H-indol-5-yl)oxy-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-27-3P,
6-Methoxy-7-(2-piperidinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-30-8P, 7-Benzyl oxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-33-1P, 7-Hydroxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-35-3P, 6-Methoxy-7-(2-morpholinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-38-6P, (S)-6-Methoxy-7-(5-oxopyrrolidin-2-ylmethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-39-7P,
4-(9H-Carbazol-2-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-41-1P, 7-[2-[N-(3,6-Dichloropyridazin-4-yl)-N-methylamino]ethoxy]-4-(indol-5-ylamino)-6-methoxyquinazoline 288385-43-3P, 4-(indol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288385-44-4P, 4-(Indol-5-ylamino)-6-methoxy-7-[(3-pyridyl)methoxy]quinazoline 288385-45-5P,
4-(Indol-5-ylamino)-6-methoxy-7-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]quinazoline 288385-47-7P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-morpholinopropoxy)quinazoline 288385-49-9P,
7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-ylamino)quinazoline
(angiogenesis inhibitor; préparation of quinazolines as angiogenesis

inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

L34 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:207937 USPATFULL

TITLE: Therapeutic combinations of antihypertensive and antiangiogenics agents

INVENTOR(S): Curwen, Jon Owen, Macclesfield, UNITED KINGDOM
Ogilvie, Donald James, Macclesfield, UNITED KINGDOM

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003144298 A1 20030731 <--

APPLICATION INFO.: US 2002-240413 A1 20021001 (10)

WO 2001-GB1522 20010402

NUMBER	DATE
--------	------

PRIORITY INFORMATION: GB 2000-8269 20000405

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 1324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003144298 A1 20030731 <--

IT 62571-86-2, Captopril 76547-98-3, Lisinopril 288383-14-2

288383-15-3 288383-16-4 288383-17-5 288383-18-6 288383-19-7

288383-20-0 288383-21-1 288383-22-2 288383-23-3

288383-24-4 288383-25-5 288383-26-6 443913-73-3

(therapeutic combinations of antihypertensive and antiangiogenic agents)

=> FIL STNGUIDE